ReviewJournal of clinical medicine2019
Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Evaluating the impact of self-management interventions on COPD outcomes in low- and middle-income countries in Asia: a systematic review.Health and quality of life outcomes · 2025Pooled it
- Effect ofFrontiers in pharmacology · 2025Pooled it
- Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.Acta pharmacologica Sinica · 2026Review
- Carbon monoxide-producing probioticiScience · 2026Article
- Mechanisms and precision interventions in sarcopenia and osteoarthritis comorbidity: A narrative review.Journal of orthopaedic translation · 2026Review
- Gut microbiome-dependent IL-1 signaling is a mediator of ACVR1bioRxiv : the preprint server for biology · 2026Article
- Direct Medical Costs Associated with Multiple Sclerosis in Saudi Arabia: A Retrospective Single-Center Cost of Illness Analysis.Healthcare (Basel, Switzerland) · 2025Article
- T-cell and autoantibody profiling for primary immune regulatory disorders.The Journal of allergy and clinical immunology · 2025Article
- Review
- The Role of Interleukin-24 and Downstream Pathways in Inflammatory and Autoimmune Diseases.Cell biochemistry and biophysics · 2025Review
- Synovial fluid dual-biomarker algorithm accurately differentiates osteoarthritis from inflammatory arthritis.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025Article
- Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's Disease.Gastro hep advances · 2025Article
- Development and validation of identification algorithms for five autoimmune diseases using electronic health records: a retrospective cohort study in China.Frontiers in immunology · 2025Article
- Cellular senescence defining the disease characteristics of Crohn's disease.Frontiers in immunology · 2025Article
- Achieving health equity in immune disease: leveraging big data and artificial intelligence in an evolving health system landscape.Frontiers in big data · 2025Review
- Chia nanoemulsion: anti-inflammatory mechanism, biological behavior and cellular interactions.Therapeutic delivery · 2024Article
- Potential use of antioxidants for the treatment of chronic inflammatory diseases.Frontiers in pharmacology · 2024Review
- The Role of the Intestinal Microbiome in Multiple Sclerosis-Lessons to Be Learned from Hippocrates.Biology · 2023Review
- A wireless patch for the monitoring of C-reactive protein in sweat.Nature biomedical engineering · 2023Article
- A machine learning model identifies patients in need of autoimmune disease testing using electronic health records.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Healthcare expenditures in the United States are growing at an alarming level with the Centers for Medicare and Medicaid Services (CMS) projecting that they will reach $5.7 trillion per year by 2026. Inflammatory diseases and related syndromes are growing in prevalence among Western societies. This growing population that affects close to 60 million people in the U.S. places a significant burden on the healthcare system. Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression. Patients require healthcare attention but are initially hidden from clinician's view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. The current total cost to the U.S. healthcare system is at least $90B dollars annually. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.